Acute Myelocytic Leukemia Clinical Trial
Official title:
Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia
This is an open, single-arm, phase I clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) targeting CD123 in the treatment of Acute Myelocytic Leukemia. A total of 15 patients are planned to be enrolled following up one year.
Chimeric antigen receptor (CAR)-modified T cells targeted against CD19 have demonstrated unprecedented successes in treating patients with hematopoietic and lymphoid malignancies. Besides CD19, many other molecules such as CD22, CD30,BCMA,CD123, etc. may be potential in developing the corresponding CAR-T cells to treat patients whose tumors expressing those markers. In this study, investigators will evaluate the safety and efficacy of CAR-T targeting CD123 in patients with Acute Myelocytic Leukemia. The primary goal is safety assessment including cytokine storm response and any other adverse effects. In addition, disease status after treatment will also be evaluated. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02244658 -
Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia
|
Phase 3 | |
| Completed |
NCT01462578 -
Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza)
|
Phase 2 | |
| Completed |
NCT01188798 -
Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies
|
Phase 3 | |
| Recruiting |
NCT06105658 -
Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AML
|
Phase 2 | |
| Completed |
NCT00854646 -
Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)
|
Phase 1 | |
| Completed |
NCT00152139 -
Stem Cell Transplantation for Patients With Hematologic Malignancies
|
Phase 3 | |
| Completed |
NCT00061581 -
Experimental Bone Marrow Transplant Protocol
|
Phase 2 | |
| Completed |
NCT01167166 -
Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)
|
Phase 1/Phase 2 | |
| Completed |
NCT01474681 -
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
|
Phase 1/Phase 2 | |
| Terminated |
NCT02255162 -
Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML
|
Phase 1 | |
| Active, not recruiting |
NCT01809392 -
Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
|
Phase 2/Phase 3 | |
| Recruiting |
NCT00155844 -
Studies on the Significance of CXCR4-CXCL12 on Leukemic Cells Passing Through"Marrow-Blood Barrier"
|
N/A | |
| Terminated |
NCT01621477 -
T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant
|
Phase 2 | |
| Completed |
NCT00559091 -
A Study of Ribavirin to Treat M4 and M5 Acute Myelocytic Leukemia
|
Phase 2 | |
| Completed |
NCT00015587 -
Molecular Epidemiology of Childhood Leukemia (Aka The California Childhood Leukemia Study)
|
N/A |